SUPPLEMENTAL INDENTURE TO BE DELIVERED BY SUBSEQUENT GUARANTORSSupplemental Indenture • April 18th, 2023 • Grifols SA • Pharmaceutical preparations • New York
SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”) dated as of April 25, 2022 among Tiancheng (Germany) Pharmaceutical Holdings AG, a company incorporated in Germany in the legal form of a stock corporation (Aktiengesellschaft) (the “Guaranteeing Subsidiary”), Grifols, S.A. (the “Issuer”), and BNY Mellon Corporate Trustee Services Limited, as trustee under the indenture referred to below (the “Trustee”).
SUPPLEMENTAL INDENTURESupplemental Indenture • April 18th, 2023 • Grifols SA • Pharmaceutical preparations • New York
This SUPPLEMENTAL INDENTURE, dated as of April 21, 2022 (this “Supplemental Indenture”), among Grifols, S.A., Grifols Biologicals LLC, Grifols International S.A., Grifols Shared Services North America, Inc., Grifols Therapeutics LLC, Grifols USA, LLC, Grifols Worldwide Operations Limited, Grifols Worldwide Operations USA, Inc. and Instituto Grifols, S.A. (each a “Guaranteeing Party”), Grifols Escrow Issuer, S.A.U. (the “Issuer”) and BNY Mellon Corporate Trustee Services Limited, as trustee (the “Trustee”), under the indenture below.
SUPPLEMENTAL INDENTURE TO BE DELIVERED BY SUBSEQUENT GUARANTORSSupplemental Indenture • April 18th, 2023 • Grifols SA • Pharmaceutical preparations • New York
SUPPLEMENTAL INDENTURE (“this Supplemental Indenture”) dated as of April 21, 2022 among Grifols Escrow Issuer, S.A.U. (the “Guaranteeing Subsidiary”), Grifols, S.A. (the “Issuer”), BNY Mellon Corporate Trustee Services Limited, as trustee under the indenture referred to below (in such capacity, the “Trustee”) and The Bank of New York Mellon, London Branch, as notes collateral agent (in such capacity, the “Notes Collateral Agent”).
SUPPLEMENTAL INDENTURESupplemental Indenture • April 18th, 2023 • Grifols SA • Pharmaceutical preparations • New York
This SUPPLEMENTAL INDENTURE, dated as of September 28, 2022 (this “Supplemental Indenture”), among Grifols Biotest Holdings GmbH, a company incorporated in Germany in the legal form of a limited liability company (Gesellschaft mit beschränkter Haftung) (the “Guaranteeing Party”), Grifols Escrow Issuer, S.A.U. (the “Issuer”) and BNY Mellon Corporate Trustee Services Limited, as trustee (the “Trustee”), under the indenture referred to below.
COUNTERPART AGREEMENTCounterpart Agreement • April 18th, 2023 • Grifols SA • Pharmaceutical preparations
This COUNTERPART AGREEMENT, dated April 21, 2022 (this “Counterpart Agreement”) is delivered pursuant to that certain Credit and Guaranty Agreement, dated November 15, 2019 (as amended prior to the date hereof and as it may be further amended, supplemented or otherwise modified, the “Credit Agreement”; the terms defined therein and not otherwise defined herein being used herein as therein defined), by and among Grifols Worldwide Operations Limited, a private company validly incorporated and existing under the laws of Ireland (the “Foreign Borrower”), Grifols Worldwide Operations USA, Inc., a Delaware corporation (the “U.S. Borrower”), Grifols, S.A., a sociedad anónima organized under the laws of the Kingdom of Spain (the “Spanish Borrower” and the “Parent” and, together with the Foreign Borrower and the U.S. Borrower, the “Borrowers”), as a Guarantor and the Spanish Borrower, and certain Subsidiaries of the Parent, as Guarantors, the Lenders party thereto from time to time, and Bank of
COUNTERPART AGREEMENTCounterpart Agreement • April 18th, 2023 • Grifols SA • Pharmaceutical preparations
This COUNTERPART AGREEMENT, dated April 25, 2022 (this “Counterpart Agreement”) is delivered pursuant to that certain Credit and Guaranty Agreement, dated November 15, 2019 (as amended prior to the date hereof and as it may be further amended, supplemented or otherwise modified, the “Credit Agreement”; the terms defined therein and not otherwise defined herein being used herein as therein defined), by and among Grifols Worldwide Operations Limited, a private company validly incorporated and existing under the laws of Ireland (the “Foreign Borrower”), Grifols Worldwide Operations USA, Inc., a Delaware corporation (the “U.S. Borrower”), Grifols, S.A., a sociedad anónima organized under the laws of the Kingdom of Spain (the “Spanish Borrower” and the “Parent” and, together with the Foreign Borrower and the U.S. Borrower, the “Borrowers”), as a Guarantor and the Spanish Borrower, and certain Subsidiaries of the Parent, as Guarantors, the Lenders party thereto from time to time, and Bank of
AMENDED AND RESTATED COUNTERPART AGREEMENTCounterpart Agreement • April 18th, 2023 • Grifols SA • Pharmaceutical preparations
This AMENDED AND RESTATED COUNTERPART AGREEMENT, dated September 23, 2022 (this “Counterpart Agreement”) is delivered pursuant to that certain Credit and Guaranty Agreement, dated November 15, 2019 (as amended prior to the date hereof and as it may be further amended, supplemented or otherwise modified, the “Credit Agreement”; the terms defined therein and not otherwise defined herein being used herein as therein defined), by and among Grifols Worldwide Operations Limited, a private company validly incorporated and existing under the laws of Ireland (the “Foreign Borrower”), Grifols Worldwide Operations USA, Inc., a Delaware corporation (the “U.S. Borrower”), Grifols, S.A., a sociedad anónima organized under the laws of the Kingdom of Spain (the “Spanish Borrower” and the “Parent” and, together with the Foreign Borrower and the U.S. Borrower, the “Borrowers”), as a Guarantor and the Spanish Borrower, and certain Subsidiaries of the Parent, as Guarantors, the Lenders party thereto from
SUPPLEMENTAL INDENTURE TO BE DELIVERED BY SUBSEQUENT GUARANTORSSupplemental Indenture • April 18th, 2023 • Grifols SA • Pharmaceutical preparations • New York
SUPPLEMENTAL INDENTURE (“this Supplemental Indenture”) dated as of April 25, 2022 among Tiancheng (Germany) Pharmaceutical Holdings AG, a company incorporated in Germany in the legal form of a stock corporation (Aktiengesellschaft) (the “Guaranteeing Subsidiary”), Grifols, S.A. (the “Issuer”), BNY Mellon Corporate Trustee Services Limited, as trustee under the indenture referred to below (in such capacity, the “Trustee”) and The Bank of New York Mellon, London Branch, as notes collateral agent (in such capacity, the “Notes Collateral Agent”).
SUPPLEMENTAL INDENTURE TO BE DELIVERED BY SUBSEQUENT GUARANTORSSupplemental Indenture • April 18th, 2023 • Grifols SA • Pharmaceutical preparations • New York
SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”) dated as of April 21, 2022 among Grifols Escrow Issuer, S.A.U. (the “Guaranteeing Subsidiary”), Grifols, S.A. (the “Issuer”), and BNY Mellon Corporate Trustee Services Limited, as trustee under the indenture referred to below (the “Trustee”).
